Clinical Trial Update: Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use

View source ↗

Summary

Prospective European registry evaluating routine use of BeneFIX for Hemophilia B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BeneFIX (recombinant coagulation factor IX concentrate)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Hemophilia B | Status: COMPLETED